elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
Lenvatinib
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Lenvatinib
RIS
0.001
(Research Intensity Score)
Papers
255
Top papers
Thyroid Cancer
2024 · 638 citations
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
2022 · 919 citations
Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies
2025 · 108 citations
Targeted therapy for hepatocellular carcinoma
2020 · 613 citations
Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma
2024 · 50 citations
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy
2025 · 20 citations
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
2024 · 40 citations
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
2019 · 335 citations
Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities
2022 · 55 citations
Newest papers
The RBMS1–SLC7A11 axis regulates ferroptosis susceptibility and lenvatinib sensitivity in hepatocellular carcinoma
2026
TACE-HAIC plus TKIs with/without PD-1 inhibitors for unresectable hepatocellular carcinoma: a propensity score matching study
2026
Editorial: Checkpoint immunotherapy: reshaping the landscape of gastrointestinal cancer treatment, volume II
2026
Targeted Therapies in Endocrine Malignancies
2026
p53-R280S mutation confers lenvatinib resistance in hepatocellular carcinoma via Bcl-2-mediated anti-apoptotic signaling
2026
OTUB1 inhibits autophagy-dependent ferroptosis in hepatocellular carcinoma by stabilizing p62 via non-canonical deubiquitination
2026
Combined effects of Lenvatinib and zinc oxide nanoparticles by promoting apoptosis and anti-proliferative activity in mice bearing Ehrlich solid tumors
2026
Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies
2025 · 108 citations
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy
2025 · 20 citations
Browse all papers →
Lenvatinib's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Lenvatinib's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link